IR@PKUHSC  > 北京大学第三临床医学院  > 药剂科
学科主题临床医学
Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies
Chen Xin; Yang Li; Zhai Suo-di
关键词Cardiovascular Risk Meta-analysis Pioglitazone Rosiglitazone Cohort Study
刊名CHINESE MEDICAL JOURNAL
2012-12-05
DOI10.3760/cma.j.issn.0366-6999.2012.23.025
125期:23页:4301-4306
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal
研究领域[WOS]General & Internal Medicine
关键词[WOS]RANDOMIZED CONTROLLED-TRIALS ; ACUTE MYOCARDIAL-INFARCTION ; HEART-FAILURE ; EVENTS ; THIAZOLIDINEDIONES ; MEDICATIONS ; MELLITUS ; DATABASE ; UPDATE ; DEATH
英文摘要

Background The difference of cardiovascular effects between rosiglitazone and pioglitazone treatment for diabetic patients has not been thoroughly studied. We performed a meta-analysis to compare the risk of cardiovascular adverse effects in patients with type 2 diabetes treated with rosiglitazone compared to pioglitazone.

Methods The Cochrane Library, Pub Med, and Embase were searched to identify retrospective cohort studies assessing cardiovascular outcomes with rosiglitazone and pioglitazone. Meta-analysis of retrospective cohort studies was conducted using Rev Man 5.0 software to calculate risk ratios.

Results Of the 74 references identified, eight studies involving 945 286 patients fit the inclusion criteria for the analysis. The results of meta-analyses showed that, compared with pioglitazone, rosiglitazone therapy significantly increased the risk of myocardial infarction (risk ratios (RR) 1.17, 95% confidence interval (CI) 1.04-1.32; P=0.01), the risk of heart failure (RR 1.18, 95% CI 1.02-1.36; P=0.03), and total mortality (RR 1.13, 95% CI 1.08-1.20; P<0.000 01).

Conclusion Compared with pioglitazone, rosiglitazone was associated with an increased risk of myocardial infarction, heart failure, and all-cause mortality in diabetic patients. Chin Med J 2012;125(23):4301-4306

语种英语
WOS记录号WOS:000312748200025
Citation statistics
Cited Times:28[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/57352
Collection北京大学第三临床医学院_药剂科
作者单位Peking Univ Third Hosp, Dept Pharm, Beijing 100191, Peoples R China
Recommended Citation
GB/T 7714
Chen Xin,Yang Li,Zhai Suo-di. Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies[J]. CHINESE MEDICAL JOURNAL,2012,125(23):4301-4306.
APA Chen Xin,Yang Li,&Zhai Suo-di.(2012).Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies.CHINESE MEDICAL JOURNAL,125(23),4301-4306.
MLA Chen Xin,et al."Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies".CHINESE MEDICAL JOURNAL 125.23(2012):4301-4306.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Chen Xin]'s Articles
[Yang Li]'s Articles
[Zhai Suo-di]'s Articles
百度学术
百度学术Similar articles in
[Chen Xin]'s Articles
[Yang Li]'s Articles
[Zhai Suo-di]'s Articles
必应学术
必应学术Similar articles in
[Chen Xin]'s Articles
[Yang Li]'s Articles
[Zhai Suo-di]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.